Sanofi’s BSI-201 tipped for success in triple negative breast cancer
pharmafile | February 28, 2010 | News story | Sales and Marketing | Cancer, PARP, Sanofi, breast cancer
Sanofi-Aventis’s BSI-201 will garner sales of $1.7 billion in the triple negative breast cancer drug market in 2018, according to Decision Resources.
The analysts says the compound has already demonstrated overall survival rates in clinical trials, and this combined with the need for novel targeted agents means BSI-201 is expected to steal significant market share from Roche’s Avastin.
The Pharmacor 2010 findings from the topic entitled Breast Cancer reveals that BSI-201, a poly ADP-ribose polymerase (PARP) inhibitor, will see considerable uptake in the treatment of triple negative breast cancer, following its anticipated launch in 2012 in the US, and in Europe and in Japan by 2014. In addition to BSI-201, other key PARP inhibitors in development include AstraZeneca’s Olaparib and Pfizer’s AG-014699.
“The inhibition of PARP has emerged as a novel therapeutic strategy in DNA repair-deficient tumours as studies suggest that combining PARP inhibition with DNA-damaging chemotherapy or radiation may have a synergistic or enhanced effect,” said Decision Resources Analyst Niamh Murphy, PhD. “Interviewed thought leaders are very optimistic about the PARP inhibitors and, in particular, about BSI-201’s potential in the triple negative breast cancer setting.”
The Pharmacor 2010 findings also reveal that recently announced clinical trial data evaluating the efficacy of Roche’s Herceptin (trastuzumab) in combination with lapatinib (GSK/Nippon Kayaku’s Tykerb/Tyverb), provides further evidence that a dual human epidermal growth factor receptor 2 (HER2)-targeted approach improves survival for patients with HER2-positive metastatic breast cancer.
Uptake of this combined treatment is, however, likely to be constrained due to competition from novel HER2-targeting agents entering the market.
“We expect that the combination of trastuzumab and lapatinib will garner sales of approximately $30 million in the world’s major markets in 2013,” Dr. Murphy said. “However, in 2018, sales of trastuzumab/lapatinib will drop to less than $20 million, due to the approval and uptake of novel HER2-targeted therapies such as Roche/Genentech/Chugai’s Herceptin-DM1, Pfizer’s neratinib and Roche/Genentech/Chugai’s pertuzumab.”
Related Content
Novartis receives SMC approval for early breast cancer treatment
Novartis has announced that its treatment for early breast cancer, Kisqali (ribociclib), has received approval …
Micrima announces upcoming launch of new UK breast cancer assessment
Breast cancer remains one of the leading health threats to women over 35 in the …
Pierre Fabre partners with Know Your Lemons Foundation for breast cancer awareness
The campaign focuses on early detection and education Pierre Fabre Laboratories has announced a partnership …
